July 23, 2023 - July 26, 2023

2023 International AIDS Society (IAS) Conference on HIV Science

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) will participate in the 12th International AIDS Society (IAS) Conference on HIV Science. As a leader in the fight for an AIDS-free generation, EGPAF staff will share research and best practices covering a variety of focus areas.

The Pre-Conference: International Workshop on HIV & Pediatrics 2023

Lynne Mofenson, Senior Technical Advisor, EGPAF, will serve as Co-Chair of the International Workshop on HIV & Pediatrics 2023

How many children and adolescents are reaching undetectable? An analysis of viral load outcomes among children and adolescents living with HIV in the Democratic Republic of Congo (Poster)

Information packaging at first contact: the gateway to improvement of health seeking behaviors and better health outcomes among pregnant and breastfeeding adolescent girls and young women in Homa Bay, Kenya (Poster)

Virological outcomes and associated factors among children living with HIV initiating or switching to pediatric dolutegravir in the Democratic Republic of Congo (Poster)

Uptake of a new pharmacovigilance tool to assess acceptability and tolerability of pediatric antiretroviral drugs in Kenya (Poster)

Consistency of multimonth antiretroviral therapy dispensing and association with viral load coverage and suppression among pediatric clients in Mozambique and Eswatini (Poster)

Follow-up outcomes of children, adolescents, and young people on darunavir-based, third-line antiretroviral therapy: observational cohort from nine African countries (Poster)

Adverse pregnancy outcomes following dolutegravir transition among women delivering at surveillance sites in Eswatini (Poster)

Satellite Sessions

Lessons Learned from Developing and Scaling Up Implementation of Programs for Advanced HIV Disease
Sunday, July 23, 2023 7:30 – 9:00
SAT002, Plaza Ballroom/Channel 3

Despite tremendous progress in the global fight against HIV/AIDS evidenced by declining HIV incidence and expanded access to antiretroviral therapy, decline in AIDS-related deaths have plateaued. Up to half of PLHIV present to care with Advanced HIV disease (AHD). Individuals with AHD are at a higher risk of death even after starting ART, and are prone to opportunistic infections including TB, severe bacterial infections, malnutrition and cryptococcal meningitis. In 2021, there were an estimated 650,000 HIV-related deaths globally, including 95,000 children. The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) supports governments in implementing AHD programs in 11 countries in Sub-Saharan Africa (SSA). SSA alone bears an estimated 60% of these deaths. With funding from PEPFAR, CDC, USAID and the Gates Foundation, EGPAF intends to highlight the programmatic lessons learned, and the real-world evidence generated from AHD program implementation in Malawi, Cote d’Ivoire and Lesotho.

Related Brief: Quantification and Supply Planning for Commodities Needed to Deliver the WHO-recommended Advanced HIV Disease Package of Care

Related Brief: An Advanced HIV Disease Differentiated Care Model in Malawi

Management of Highly Treatment-Experienced Children, Adolescents, and Youth Experiencing Treatment Failure in Sub-Saharan Africa
Sunday, July 23, 2023 9:30 – 11:00
SAT009, Plaza Auditorium/Channel 4

The Elizabeth Glaser Pediatric AIDS Foundation proposes to present the results of the New Horizons Study, a four-year study which explored data from a cohort of over 800 of children, adolescents and young adults (ages 0-24 years) who ever received Darunavir (DRV) and/or Etravirine (ETR) as part of second- or third-line antiretroviral therapy in 9 African countries: Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. An overview of patient characteristics, prevalence of drug resistance mutations, and viral suppression after initiation on DRV and/or ETR will be shared, along with case studies highlighting different national models for improving the care of highly treatment-experienced young people. A panel of experts will lead a discussion on how to detect treatment failure, sequence ART regimens, and the next steps needed to improve the quality of life for these priority populations.

Oral Presentations

Cost-effectiveness of the WHO-endorsed advanced HIV care package in Malawi

Posters

Adverse pregnancy outcomes following dolutegravir transition among women delivering at surveillance sites in Eswatini

Digitizing the monitoring of quality improvement activities to strengthen quality of care for people living with HIV in nine sub-Saharan African countries: EGPAF’s QI-PM application

Managing pediatric and adolescent treatment failure among children and adolescents living with HIV in seven sub-Saharan African countries

Consistency of multimonth antiretroviral therapy dispensing and association with viral load coverage and suppression among pediatric clients in Mozambique and Eswatini

Related Resources

Gap-f Paediatric DTG Implementation Considerations for National Programmes

Guidance and Tools to Strengthen Pharmacovigilance for Pediatric Medicines, with a Focus on New Antiretroviral Treatment Regimens in Resource-Limited Settings

Multimonth ART: What Do Patient Care and Outcomes Look Like Within the First Year? Results from Studies in Cote d’Ivoire, Mozambique, and Eswatini

Digitizing Quality Improvement, Program Optimization, and Technical Assistance: Four of EGPAF’s Web and Mobile App Solutions

Advanced HIV Disease and Opportunistic Infection

Paediatric Abacavir/Lamivudine/ Dolutegravir (pALD) Fixed-Dose Combination

Management of Treatment Failure for Pediatric and Adolescent Patients